Glioblastoma is the most common and lethal primary intracranial tumor. As the key regulator of tumor cell volume, sodium-potassium-chloride cotransporter 1 (NKCC1) expression increases along with the malignancy of the glioma, and NKCC1 has been implicated in glioblastoma invasion. However, little is known about the role of NKCC1 in the epithelial-mesenchymal transition-like process in gliomas. We noticed that aberrantly elevated expression of NKCC1 leads to changes in the shape, polarity, and adhesion of cells in glioma. Here, we investigated whether NKCC1 promotes an epithelialmesenchymal transition (EMT)-like process in gliomas via the RhoA and Rac1 signaling pathways. Pharmacological inhibition and knockdown of NKCC1 both decrease the expressions of mesenchymal markers, such as N-cadherin, vimentin, and snail, whereas these treatments increase the expression of the epithelial marker E-cadherin. These findings indicate that NKCC1 promotes an EMT-like process in gliomas. The underlying mechanism is the facilitation of the binding of Rac1 and RhoA to GTP by NKCC1, which results in a significant enhancement of the EMT-like process. Specific inhibition or knockdown of NKCC1 both attenuate activated Rac1 and RhoA, and the pharmacological inhibitions of Rac1 and RhoA both impair the invasion and migration abilities of gliomas.
| INTRODUCTION
Glioblastoma multiforme (GBM) is one of the most lethal human tumors. Most GBM patients without treatment die within 3 months of diagnosis (Stupp et al., 2005 (Stupp et al., , 2009 . Even with surgical intervention combined with chemo-and radiation therapies, the median survival time for GBM is still 12-16 months (Preusser et al., 2011) . Due to its highly invasive nature, GBM is the most aggressive form of brain cancer, which impedes the surgical removal of all tumor cells and makes relapse inevitable. Hence, to improve the current poor prognosis of GBM patients, the identification of effective therapeutic targets to impede intracranial invasion and the spread of tumor cells is imperative.
The sodium-potassium-chloride cotransporter 1 (NKCC1), also known as solute carrier family 12 member 2 (SLC12A2), transports one sodium ion, one potassium ion, and two chloride ions across the plasma membrane and is sensitive to loop diuretics. It has been reported that NKCC1 is highly expressed in gliomas and is tightly related to many malignancies. Pharmacological inhibition of ion cotransport reduces the ability of tumors to spread, and the agonists of the ion cotransport markedly increase their spread (Cong, Zhu, Kuo, Hu, & Sun, 2015) . Moreover, the inhibition of NKCC1 accelerates temozolomide-mediated apoptosis in glioblastoma cells (Algharabil et al., 2012) . The overexpression of NKCC1 induces cell proliferation and phenotypic transformation in mouse fibroblasts (Panet, Marcus, & Atlan, 2000) . Moreover, it has been demonstrated that NKCC1 plays an important role in the proliferation of gastric and prostate cancer cells (Hiraoka et al., 2010; Shiozaki et al., 2006) . Shiozaki et al. (2014) also suggested that NKCC1 plays an important role in cell cycle progression in human esophageal squamous cell carcinomas. It is well known that the infiltrative growth pattern is one of the most significant characteristics of malignant gliomas, and the transformation ability of tumor cells to cross the narrow extracellular space is crucial for infiltration (Cuddapah & Sontheimer, 2011) . This evidence indicates that NKCC1 is a key protein in carcinogenesis and that NKCC1 could become a new therapeutic target for the malignancy, but the related potential mechanisms of carcinogenesis have not yet been elucidated.
Epithelial-mesenchymal transition (EMT) is a complex process
involving a high level of phenotypic plasticity that enables epithelial cells to lose their cell polarity and cell adhesion and gain migratory and invasive properties, which leads to a mesenchymal phenotype.
Moreover, EMT is thought to be essential for tumor metastasis in systemic cancers (Tam & Weinberg, 2013) . Although some debates still exist regarding the EMT concept in gliomas, an "EMT-like" process is accepted in brain tumors (Iser, Pereira, Lenz, & Wink, 2017) . The EMT-like process refers to an intermediate phenotype that turns into a phenotype that is less epithelial and more mesenchymal (Iser et al., 2017) . Although glioblastoma patients rarely exhibit extracranial metastasis complications, it is surprising that approximately 20% of GBM patients have detectable levels of circulating tumor cells in their blood (Awan et al., 2015) . Hence, the EMT-like process has been proposed to play a very important role in the spread and metastasis of GBM. Several pathways have been found to regulate the EMT, including NF-κB, Wnt, PI3k/Akt, and so forth (Maier, Traenkle, & Rothbauer, 2016) . Recently, additional studies have demonstrated that the Rac1 and RhoA pathways play pivotal roles in the EMT process (Gulhati et al., 2011; Schiapparelli et al., 2017; Zhang et al., 2014) .
In the initial steps of metastasis, some important regulatory factors involving the activation of small GTPases, including RhoA and Rac1, play a crucial role in actin cytoskeletal rearrangement and cell migration (Hall, 1998) . For example, Rho GTPases regulate many important cellular processes including cytoskeletal remodeling (Ellenbroek & Collard, 2007) . Bar-Sagi and Hall (2000) support the notion that crosstalk between Ras and Rho proteins is involved in several biological processes, including cell transformation, cell migration, and the EMT. In summary, Rho GTPases play an important role in the EMT process in tumors, and this process is closely correlated with the malignancy of tumors. In colorectal carcinoma, Rac1 and RhoA act as an intercurrent signaling pathway that regulates the EMT and tumor metastasis (Gulhati et al., 2011) .
Additionally, in breast cancer, Rac1, RhoA, and cdc42 also serve as regulators of the EMT .
In this study, we suggest that NKCC1 was highly expressed in GBMs with surrounding multifocal infiltration and spread, and NKCC1 promoted the invasion and migration of gliomas. Furthermore, NKCC1
promoted the EMT-like process in gliomas via the RhoA and Rac1 signaling pathways; inhibition of NKCC1 significantly impaired the aggressive progression of gliomas in vitro and in vivo, which indicated that NKCC1 serves as a potential therapeutic target for the inhibition of the dissemination of gliomas.
| MATERIALS AND METHODS

| Cell culture and reagents
Two human malignant glioma cell lines (U87-MG, SNB19) were purchased from the Institute of Biochemistry and Cell Biology (Shanghai, China) and were cultured in Dulbecco modified Eagle medium (Gibco, Invitrogen Inc., Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco) and incubated at 37℃ in 5% CO 2 . 
| Western blot analysis
Total cell lysate was prepared as described previously [13] . After denaturation, the proteins were separated by gel electrophoresis using 10% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA). After being washed three times by Tris-buffered Saline with Tween 20 (TBST), the membrane was blocked by 5% bovine serum albumin (BSA) for 1 hr at 37°C. 
| Immunofluorescence analysis
Different cells were seeded onto cover slips in a 12-well plate overnight. The cells were washed with phosphate buffer saline (PBS) three times and fixed with 4% paraformaldehyde for 10 min. Then, they were permeabilized with 0.1% Triton X-100 for 10 min (except membrane antigen) and blocked in 5% BSA at room temperature for 30 min. They were then incubated with a primary antibody at 4°C overnight. After being rewarmed for 1 hr, the samples were washed with PBS three times and incubated with specific secondary antibodies for 1 hr at 37°C. After washing three times with PBS, the nuclei were stained with 4',6-Diamidino-2-Phenylindole (DAPI)
for 5 min at room temperature. Immunofluorescence was observed using fluorescence microscopy (Olympus, Japan).
| Transwell and wound-healing assay
Cell migration and invasion assays were carried out as described previously (Zhu et al., 2014) .
| Pull-down assays
RhoA and Rac1 activity was assessed using the GST-tagged Rhobinding domain of Rhotekin (TRBD) and the GST-tagged p21 binding domain of PAK1 (GST-PBD) pull-down assays, respectively, as described previously (Gulhati et al., 2011; O'Connor, Nguyen, & Mercurio, 2000) . Briefly, the cells were grown to~70% confluency in regular growth medium and stimulated with EGF (50 ng/ml) for 5 min. For BMT treatment, the cells were preincubated in 50 μM BMT for 24 hr. The RhoA monoclonal antibody was from Cell
Signaling Technology and the Rac1 monoclonal antibody was from Millipore.
| Gelatin zymography
Equal numbers of cells were seeded in serum free conditions.
Supernatants were collected, normalized for total protein concentration, mixed with sample buffer (Invitrogen), and analyzed by electrophoresis with a 10% zymogram gel (Invitrogen) for 90 min.
The gel was developed according to the manufacturer's instructions and stained with Coomassie Blue (Invitrogen).
| Lentiviral transfection
Lentiviral shRNA constructs were obtained from Genechem Co., Ltd., China. ShRNA sequences were as follows: TCAGGCTCTATGTAAG GAC (shNKCC1-1), CACTATCGTAACAGAGCTA (shNKCC1-2). Firefly Luciferase lentiviral particles were obtained from Genechem Co., Ltd. Cells were transfected with either lentiviral particles, following the manufacturer's recommendations. After infection, stable cell clones expressing the shRNA constructs were isolated by selection with 5 μg/ml puromycin solution. The cells were collected for further experiments at 48 hr after the transfection.
| Immunohistochemical staining
Paraffin-embedded tumors were sectioned and dewaxed. After antigen retrieval (treated in 10 mmol/L citrate buffer for 20 min at 95°C), sections were cleared of endogenous peroxidase activity by incubation with 3% H 2 O 2 for 15 min and blocked with 5% BSA for 30 min at 37°C. They were then incubated with primary antibodies at 4°C overnight. The next day, after rewarming for 1 hr, sections were incubated with biotinylated secondary antibodies for 1 hr at 37°C. They were then incubated with ABC-peroxidase for 1 hr before sections were colored using a DAB Kit (ZSGB-BIO) and counterstained with haematoxylin.
After dehydration, sections were examined using a light microscope. 
| Animals and intracranial xenograft model
| Statistical analysis
All quantified data represent an average of at least triplicate experiments, unless otherwise indicated. Standard deviations were calculated. All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA). Comparisons among groups were performed using unpaired Student t tests. p < 0.05 was considered to be statistically significant. (ICH) samples from high grade glioma (HGG) groups taken from the Human Protein Atlas stained stronger for NKCC1 than did samples from LGG groups (Supporting Information Figure S1B ). Together, these findings strongly indicate that NKCC1 plays a critical role in intracranial GBM dissemination and is related to patient prognosis.
| NKCC1 was significantly correlated with a mesenchymal phenotype in GBM
Based on the TCGA database, the NKCC1 expression was higher in GBM tissues than in normal brain tissues (Figure 2b) . 
| Inhibition of NKCC1 decreased invasion and migration
The NKCC1 expression levels in malignant glioma cell lines (NA, U87MG, U251MG, SNB19, LNZ308, LN18, TJ905) were detected by western blotting. The U87-MG and SNB19 cells exhibited higher levels of expression of NKCC1 than did the NA, U251MG, LNZ308, LN18, TJ905, and LNZ308 cells (Supporting Information Figure S1D ).
Immunofluorescence staining revealed that NKCC1 was distributed to the leading site of migrating cells (Supporting Information Figure   S1A ). A CCK-8 assay (Dojindo Laboratories) was performed to ensure that the drug concentration that we selected in this study did not affect the proliferation abilities of U87-MG (IC 50 = 0.6 mM) or SNB19 cells (IC 50 = 1 mM; Supporting Information Figure S1C ). Next, we used BMT, a specific inhibitor of NKCC1 (Lee et al., 2003) , to evaluate the invasion and migration abilities of U87-MG and SNB19 cells as influenced by NKCC1 using a Transwell assay and a woundhealing assay (Figure 3a,b) . Moreover, we used two shRNAs (shNKCC1-1 and shNKCC1-2) that targeted NKCC1 (Figure 3d ). 
| NKCC1 promoted EMT in U87-MG and SNB19 cells
A single-cell colon assay was performed to demonstrate that NKCC1
knockdown resulted in greater cell adhesion, the maintenance of more compact contact with neighboring cells, and a tendency toward an epithelial morphology (Supporting Information Figure S2B ).
Additionally, we demonstrated that the expressions of EMT-related 
| Rac1 and RhoA signaling mediated NKCC1-induced EMT
To further investigate the underlying mechanism, the TCGA data set was searched to demonstrate that the expression of the SLC12A2 gene was positively correlated with the expressions of the RAC1 and RHOA genes (Figure 5a ; p < 0.0001). RhoA and Rac1 belong to a family of GTPases that regulate F-actin assembly and disassembly while controlling cell migration. As illustrated in Figure 5d , we performed GST-TRBD and GST-PBD pull-down assays, and RhoA We noticed that GBM patients with surrounding multifocal infiltration and spread exhibited high levels of expression of NKCC1
in the center and border of the tumors. NKCC1 initially received attention as a key tumor cell volume regulator. NKCC1 is widely distributed in various tissues of the human body, is overexpressed in GBM tissue, and is tightly related to many malignancies. Recently, it was reported that high levels of NKCC1 expression predict poor clinical outcomes for lung adenocarcinoma patients and an epidermal growth factor receptor (EGFR)-mutated subgroup (Sun et al., 2016) .
In esophageal squamous cell carcinoma, the expression of NKCC1 might be related to the degree of histological differentiation (Shiozaki et al., 2014) . A growing amount of data demonstrates that cell migration and invasion are facilitated by ion channels and transporters (Sontheimer, 2008) . NKCC1 imbues glioma cells with a great transformation power that enables them to cross the extremely narrow extracellular space; the volume of a migrating glioma cell can be reduced to 30%-50% of the initial volume (Watkins & Sontheimer, 2011) . Additionally, in the latest research, NKCC1 has been observed to regulate the cytoskeleton in addition to cell volume. Upon NKCC1 knockdown, there is a decreased expression of Cofilin1 at the plasma membrane coupled with decreases in RhoA and Rac1 activities (Schiapparelli et al., 2017) . Therefore, NKCC1 plays a pivotal role in many processes related to the malignant phenotype of gliomas.
We initially verified that NKCC1 promoted the EMT process in gliomas. In our experiment, we found that high NKCC1 expression in glioma cells tended to change their shape and polarity and the cell adhesion with adjacent cells; that is the cell phenotype was changed.
Although there are some different features and behavioral patterns between the EMT-like process in neuroepithelial tumors and the classical EMT process in traditional epithelial tumors, many mesenchymal markers play important roles in glioma malignancy. For example, snail promotes proliferation, migration and invasion through the induction of the EMT process in glioblastomas in vitro (Myung, Choi, Kim, Wang, & Park, 2014) . Slug promotes the invasion and migration of gliomas in vitro and facilitates the growth of glioblastomas and angiogenesis in vivo (H.W. Yang, Menon, Black, Carroll, & Johnson, 2010) . Moreover, Twist1 accelerates the invasive abilities of GBM by increasing the mesenchymal phenotype (Mikheeva et al., 2010) . Therefore, the terms "glial-to-mesenchymal transition" or EMT-like process, which are substitutes for EMT in gliomas, have been increasingly proposed (Iser et al., 2017; Mahabir et al., 2014) .
Although GBM is characterized by a locally aggressive pattern, it rarely produces clinically evident extra-cranial metastases, with only 0.4% of cases experiencing metastases to visceral organs, including the liver, spleen, kidney, and skin (Smith, Hardman, & Earle, 1969) .
Nevertheless, approximately 20% of GBM patients have detectable levels of circulating tumor cells in their blood (Awan et al., 2015) . A recent study demonstrated that single GBM CTCs isolated from both patients and mouse PDX models exhibit enrichment of mesenchymal over neural differentiation markers (Sullivan et al., 2014) . Moreover, circulating tumor cells from metastatic breast cancer patients exhibit heterogeneous epithelial and mesenchymal phenotypes, and CTCs display higher levels of the mesenchymal phenotype than carcinoma cells within primary tumors (Yu et al., 2013) . Therefore, the mesenchymal transformation is a pivotal molecular event that increases the malignancy of glial tumors (Kahlert, Nikkhah, & Maciaczyk, 2013) .
Based on our experimental research, we hypothesized that NKCC1 promotes the EMT-like process in gliomas via the RhoA and Rac1 signaling pathways. Moreover, numerous studies also support our supposition. Rac1 activation mediates Twist1-induced cancer cell migration (W.H. Yang et al., 2012) . Rac1 overexpression is correlated with the epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer (Zhou et al., 2016) . Rac1 promotes the EMT program in gastric adenocarcinomas and the acquisition of a cancer stem cell state. Rac1 inhibition in gastric adenocarcinoma cells blocks EMT and CSC phenotypes and thus prevents metastasis and may augment chemotherapy (Yoon et al., 2017) . These studies and our experimental data provide theoretical support for the mechanism by which NKCC1 promotes EMT.
| CONCLUSIONS
Our research suggests that NKCC1 can regulate glioma cell migration and invasion abilities in vitro and in vivo. We primarily confirmed that NKCC1 promoted the EMT-like process in gliomas.
More important, we confirmed that NKCC1 accelerates EMT in glioblastoma cells via NKCC1-dependent Rac1/RhoA activation. Our findings also suggest that NKCC1 could serve as a potential new target for the treatment of malignant glioma. Moreover, NKCC1 can be targeted by the FDA-approved drug BMT, which has been demonstrated to decrease GBM migration in vitro and in vivo (Haas & Sontheimer, 2010) . Unfortunately, bumetanide cannot effectively cross the blood brain barrier. Therefore, a new NKCC1 inhibitor that can block NKCC1 in the brain is expected and could be used in combination with the conventional chemotherapy drug temozolomide to disrupt the spread and dissemination of gliomas.
